Karyopharm Therapeutics (NASDAQ: KPTI) has announced enrollment completion in its Phase 3 SENTRY trial, designed to evaluate selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis (MF) patients.
According to Karyopharm, topline results from the SENTRY trial are expected in March 2026.
In a statement, Richard Paulson, president and CEO of Karyopharm, commented, in part, “Selinexor plus ruxolitinib has the potential to be the first combination therapy approved for the treatment of MF, depending on the outcome of the data. By combining selinexor with the current standard of care, we believe we have the potential to redefine the way people living with MF are treated.”
Reshma Rangwala, MD, PhD, CMO and head of research of Karyopharm, remarked, “I am grateful for the patients, their families and caregivers, the investigators and their clinical trial staff, as well as the extraordinary efforts of the Karyopharm team and our external partners for their help in successfully achieving this important milestone.”
Dr. Rangwala added, “This trial is advancing our understanding of the treatment of MF and the potential role that XPO1 inhibition may play in this disease. People living with MF deserve new treatment options and everyone involved in SENTRY is making an important contribution towards our common goal of providing additional options to patients with this disease.”
